Publications by authors named "R T Casey"
Managing Hypoglycaemia in Patients With Insulinoma-A Tertiary Centre Experience and Review of the Literature.
Clin Endocrinol (Oxf)
December 2024
Article Synopsis
- Managing hypoglycaemia is crucial for insulinoma patients, especially around surgery and in ongoing treatment for inoperable cases.
- Many patients experience severe and disabling hypoglycaemia due to impaired awareness, increasing the risk of life-threatening episodes.
- The text outlines an algorithm for hypoglycaemia management based on disease stage and discusses nutritional and pharmacological strategies, including various medications and therapies.
There is limited knowledge about the size of the UK dog population. This makes it difficult to reliably monitor population dynamics and management. A repeatable method of measuring the UK dog population, including owned and unowned dogs i.
View Article and Find Full Text PDFSeparation-related behaviours (SRBs) in dogs () often indicate poor welfare. Understanding SRB risk factors can aid prevention strategies. We investigated whether early-life experiences and dog-owner interactions affect SRB development.
View Article and Find Full Text PDFCurrent views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines.
Best Pract Res Clin Endocrinol Metab
November 2024
Article Synopsis
- Phaeochromocytoma and paraganglioma (PPGL) are rare tumors that develop from specialized cells in the adrenal gland or nearby nerve tissues, affecting both adults and, less commonly, children.
- The annual incidence in children is approximately 0.5 cases per million, and there's been significant progress in understanding how to diagnose and treat these tumors, primarily based on adult studies.
- This article reviews the unique challenges and management strategies for diagnosing and treating pediatric PPGL, including recent international guidelines.
Article Synopsis
- The study aimed to compare disability progression between primary progressive multiple sclerosis (PPMS) patients treated with anti-CD20 therapies (rituximab and ocrelizumab) and a control group that was untreated.
- Data was gathered retrospectively from the French MS registry, including factors like time to confirmed disability progression (CDP), relapse rates, and MRI activity in patients from 2016 to 2021.
- Results showed no significant difference in CDP or MRI activity between treated and untreated groups, although a trend suggested treated patients might experience fewer relapses, warranting further investigation.